pembrolizumab
merck
['kn407']
5-year survival update for kn407 : 19% 5y survival in itt. however in pdl1 negative sqnscl despite higher orr, hr 0.83 (0.61 - 1.13) and no major difference in median os. 
MD MSc, Thoracic Oncology & Respiratory Medicine, master in hospital and health care management Hasselt - Belgium - PhD candidate Amsterdam/Leiden - he/him